Medical Care
Global Highly Active Antiretroviral Therapy (HAART) Market Research Report 2025
- May 12, 25
- ID: 236210
- Pages: 87
- Figures: 88
- Views: 2
The global market for Highly Active Antiretroviral Therapy (HAART) was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
North American market for Highly Active Antiretroviral Therapy (HAART) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Highly Active Antiretroviral Therapy (HAART) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Highly Active Antiretroviral Therapy (HAART) in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Highly Active Antiretroviral Therapy (HAART) include Gilead, Roche, ViiV Healthcare, Boehringer Ingelheim, Johnson and Johnson, Mylan, Bionor Pharma, Vertex Pharmaceuticals, Merck, CIPLA, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Highly Active Antiretroviral Therapy (HAART), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Highly Active Antiretroviral Therapy (HAART).
The Highly Active Antiretroviral Therapy (HAART) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Highly Active Antiretroviral Therapy (HAART) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Highly Active Antiretroviral Therapy (HAART) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Gilead
Roche
ViiV Healthcare
Boehringer Ingelheim
Johnson and Johnson
Mylan
Bionor Pharma
Vertex Pharmaceuticals
Merck
CIPLA
AbbVie
Segment by Type
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Protease Inhibitor (PI)
Segment by Application
Hospital
Clinic
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Highly Active Antiretroviral Therapy (HAART) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
North American market for Highly Active Antiretroviral Therapy (HAART) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Highly Active Antiretroviral Therapy (HAART) is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The global market for Highly Active Antiretroviral Therapy (HAART) in Hospital is estimated to increase from $ million in 2024 to $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Highly Active Antiretroviral Therapy (HAART) include Gilead, Roche, ViiV Healthcare, Boehringer Ingelheim, Johnson and Johnson, Mylan, Bionor Pharma, Vertex Pharmaceuticals, Merck, CIPLA, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Highly Active Antiretroviral Therapy (HAART), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Highly Active Antiretroviral Therapy (HAART).
The Highly Active Antiretroviral Therapy (HAART) market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Highly Active Antiretroviral Therapy (HAART) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Highly Active Antiretroviral Therapy (HAART) companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Gilead
Roche
ViiV Healthcare
Boehringer Ingelheim
Johnson and Johnson
Mylan
Bionor Pharma
Vertex Pharmaceuticals
Merck
CIPLA
AbbVie
Segment by Type
Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Protease Inhibitor (PI)
Segment by Application
Hospital
Clinic
Other
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Highly Active Antiretroviral Therapy (HAART) company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Highly Active Antiretroviral Therapy (HAART) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Nucleoside Reverse Transcriptase Inhibitors (NRTI)
1.2.3 Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
1.2.4 Protease Inhibitor (PI)
1.3 Market by Application
1.3.1 Global Highly Active Antiretroviral Therapy (HAART) Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Highly Active Antiretroviral Therapy (HAART) Market Perspective (2020-2031)
2.2 Global Highly Active Antiretroviral Therapy (HAART) Growth Trends by Region
2.2.1 Global Highly Active Antiretroviral Therapy (HAART) Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Highly Active Antiretroviral Therapy (HAART) Historic Market Size by Region (2020-2025)
2.2.3 Highly Active Antiretroviral Therapy (HAART) Forecasted Market Size by Region (2026-2031)
2.3 Highly Active Antiretroviral Therapy (HAART) Market Dynamics
2.3.1 Highly Active Antiretroviral Therapy (HAART) Industry Trends
2.3.2 Highly Active Antiretroviral Therapy (HAART) Market Drivers
2.3.3 Highly Active Antiretroviral Therapy (HAART) Market Challenges
2.3.4 Highly Active Antiretroviral Therapy (HAART) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Highly Active Antiretroviral Therapy (HAART) Players by Revenue
3.1.1 Global Top Highly Active Antiretroviral Therapy (HAART) Players by Revenue (2020-2025)
3.1.2 Global Highly Active Antiretroviral Therapy (HAART) Revenue Market Share by Players (2020-2025)
3.2 Global Highly Active Antiretroviral Therapy (HAART) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Highly Active Antiretroviral Therapy (HAART) Revenue
3.4 Global Highly Active Antiretroviral Therapy (HAART) Market Concentration Ratio
3.4.1 Global Highly Active Antiretroviral Therapy (HAART) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Highly Active Antiretroviral Therapy (HAART) Revenue in 2024
3.5 Global Key Players of Highly Active Antiretroviral Therapy (HAART) Head office and Area Served
3.6 Global Key Players of Highly Active Antiretroviral Therapy (HAART), Product and Application
3.7 Global Key Players of Highly Active Antiretroviral Therapy (HAART), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Highly Active Antiretroviral Therapy (HAART) Breakdown Data by Type
4.1 Global Highly Active Antiretroviral Therapy (HAART) Historic Market Size by Type (2020-2025)
4.2 Global Highly Active Antiretroviral Therapy (HAART) Forecasted Market Size by Type (2026-2031)
5 Highly Active Antiretroviral Therapy (HAART) Breakdown Data by Application
5.1 Global Highly Active Antiretroviral Therapy (HAART) Historic Market Size by Application (2020-2025)
5.2 Global Highly Active Antiretroviral Therapy (HAART) Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Highly Active Antiretroviral Therapy (HAART) Market Size (2020-2031)
6.2 North America Highly Active Antiretroviral Therapy (HAART) Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2020-2025)
6.4 North America Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Highly Active Antiretroviral Therapy (HAART) Market Size (2020-2031)
7.2 Europe Highly Active Antiretroviral Therapy (HAART) Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2020-2025)
7.4 Europe Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Highly Active Antiretroviral Therapy (HAART) Market Size (2020-2031)
8.2 Asia-Pacific Highly Active Antiretroviral Therapy (HAART) Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Highly Active Antiretroviral Therapy (HAART) Market Size by Region (2020-2025)
8.4 Asia-Pacific Highly Active Antiretroviral Therapy (HAART) Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Highly Active Antiretroviral Therapy (HAART) Market Size (2020-2031)
9.2 Latin America Highly Active Antiretroviral Therapy (HAART) Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2020-2025)
9.4 Latin America Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Highly Active Antiretroviral Therapy (HAART) Market Size (2020-2031)
10.2 Middle East & Africa Highly Active Antiretroviral Therapy (HAART) Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2020-2025)
10.4 Middle East & Africa Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Gilead
11.1.1 Gilead Company Details
11.1.2 Gilead Business Overview
11.1.3 Gilead Highly Active Antiretroviral Therapy (HAART) Introduction
11.1.4 Gilead Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
11.1.5 Gilead Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Highly Active Antiretroviral Therapy (HAART) Introduction
11.2.4 Roche Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
11.2.5 Roche Recent Development
11.3 ViiV Healthcare
11.3.1 ViiV Healthcare Company Details
11.3.2 ViiV Healthcare Business Overview
11.3.3 ViiV Healthcare Highly Active Antiretroviral Therapy (HAART) Introduction
11.3.4 ViiV Healthcare Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
11.3.5 ViiV Healthcare Recent Development
11.4 Boehringer Ingelheim
11.4.1 Boehringer Ingelheim Company Details
11.4.2 Boehringer Ingelheim Business Overview
11.4.3 Boehringer Ingelheim Highly Active Antiretroviral Therapy (HAART) Introduction
11.4.4 Boehringer Ingelheim Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
11.4.5 Boehringer Ingelheim Recent Development
11.5 Johnson and Johnson
11.5.1 Johnson and Johnson Company Details
11.5.2 Johnson and Johnson Business Overview
11.5.3 Johnson and Johnson Highly Active Antiretroviral Therapy (HAART) Introduction
11.5.4 Johnson and Johnson Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
11.5.5 Johnson and Johnson Recent Development
11.6 Mylan
11.6.1 Mylan Company Details
11.6.2 Mylan Business Overview
11.6.3 Mylan Highly Active Antiretroviral Therapy (HAART) Introduction
11.6.4 Mylan Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
11.6.5 Mylan Recent Development
11.7 Bionor Pharma
11.7.1 Bionor Pharma Company Details
11.7.2 Bionor Pharma Business Overview
11.7.3 Bionor Pharma Highly Active Antiretroviral Therapy (HAART) Introduction
11.7.4 Bionor Pharma Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
11.7.5 Bionor Pharma Recent Development
11.8 Vertex Pharmaceuticals
11.8.1 Vertex Pharmaceuticals Company Details
11.8.2 Vertex Pharmaceuticals Business Overview
11.8.3 Vertex Pharmaceuticals Highly Active Antiretroviral Therapy (HAART) Introduction
11.8.4 Vertex Pharmaceuticals Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
11.8.5 Vertex Pharmaceuticals Recent Development
11.9 Merck
11.9.1 Merck Company Details
11.9.2 Merck Business Overview
11.9.3 Merck Highly Active Antiretroviral Therapy (HAART) Introduction
11.9.4 Merck Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
11.9.5 Merck Recent Development
11.10 CIPLA
11.10.1 CIPLA Company Details
11.10.2 CIPLA Business Overview
11.10.3 CIPLA Highly Active Antiretroviral Therapy (HAART) Introduction
11.10.4 CIPLA Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
11.10.5 CIPLA Recent Development
11.11 AbbVie
11.11.1 AbbVie Company Details
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Highly Active Antiretroviral Therapy (HAART) Introduction
11.11.4 AbbVie Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
11.11.5 AbbVie Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Highly Active Antiretroviral Therapy (HAART) Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Nucleoside Reverse Transcriptase Inhibitors (NRTI)
1.2.3 Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
1.2.4 Protease Inhibitor (PI)
1.3 Market by Application
1.3.1 Global Highly Active Antiretroviral Therapy (HAART) Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Highly Active Antiretroviral Therapy (HAART) Market Perspective (2020-2031)
2.2 Global Highly Active Antiretroviral Therapy (HAART) Growth Trends by Region
2.2.1 Global Highly Active Antiretroviral Therapy (HAART) Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Highly Active Antiretroviral Therapy (HAART) Historic Market Size by Region (2020-2025)
2.2.3 Highly Active Antiretroviral Therapy (HAART) Forecasted Market Size by Region (2026-2031)
2.3 Highly Active Antiretroviral Therapy (HAART) Market Dynamics
2.3.1 Highly Active Antiretroviral Therapy (HAART) Industry Trends
2.3.2 Highly Active Antiretroviral Therapy (HAART) Market Drivers
2.3.3 Highly Active Antiretroviral Therapy (HAART) Market Challenges
2.3.4 Highly Active Antiretroviral Therapy (HAART) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Highly Active Antiretroviral Therapy (HAART) Players by Revenue
3.1.1 Global Top Highly Active Antiretroviral Therapy (HAART) Players by Revenue (2020-2025)
3.1.2 Global Highly Active Antiretroviral Therapy (HAART) Revenue Market Share by Players (2020-2025)
3.2 Global Highly Active Antiretroviral Therapy (HAART) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Highly Active Antiretroviral Therapy (HAART) Revenue
3.4 Global Highly Active Antiretroviral Therapy (HAART) Market Concentration Ratio
3.4.1 Global Highly Active Antiretroviral Therapy (HAART) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Highly Active Antiretroviral Therapy (HAART) Revenue in 2024
3.5 Global Key Players of Highly Active Antiretroviral Therapy (HAART) Head office and Area Served
3.6 Global Key Players of Highly Active Antiretroviral Therapy (HAART), Product and Application
3.7 Global Key Players of Highly Active Antiretroviral Therapy (HAART), Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Highly Active Antiretroviral Therapy (HAART) Breakdown Data by Type
4.1 Global Highly Active Antiretroviral Therapy (HAART) Historic Market Size by Type (2020-2025)
4.2 Global Highly Active Antiretroviral Therapy (HAART) Forecasted Market Size by Type (2026-2031)
5 Highly Active Antiretroviral Therapy (HAART) Breakdown Data by Application
5.1 Global Highly Active Antiretroviral Therapy (HAART) Historic Market Size by Application (2020-2025)
5.2 Global Highly Active Antiretroviral Therapy (HAART) Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Highly Active Antiretroviral Therapy (HAART) Market Size (2020-2031)
6.2 North America Highly Active Antiretroviral Therapy (HAART) Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2020-2025)
6.4 North America Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Highly Active Antiretroviral Therapy (HAART) Market Size (2020-2031)
7.2 Europe Highly Active Antiretroviral Therapy (HAART) Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2020-2025)
7.4 Europe Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Highly Active Antiretroviral Therapy (HAART) Market Size (2020-2031)
8.2 Asia-Pacific Highly Active Antiretroviral Therapy (HAART) Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Highly Active Antiretroviral Therapy (HAART) Market Size by Region (2020-2025)
8.4 Asia-Pacific Highly Active Antiretroviral Therapy (HAART) Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Highly Active Antiretroviral Therapy (HAART) Market Size (2020-2031)
9.2 Latin America Highly Active Antiretroviral Therapy (HAART) Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2020-2025)
9.4 Latin America Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Highly Active Antiretroviral Therapy (HAART) Market Size (2020-2031)
10.2 Middle East & Africa Highly Active Antiretroviral Therapy (HAART) Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2020-2025)
10.4 Middle East & Africa Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Gilead
11.1.1 Gilead Company Details
11.1.2 Gilead Business Overview
11.1.3 Gilead Highly Active Antiretroviral Therapy (HAART) Introduction
11.1.4 Gilead Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
11.1.5 Gilead Recent Development
11.2 Roche
11.2.1 Roche Company Details
11.2.2 Roche Business Overview
11.2.3 Roche Highly Active Antiretroviral Therapy (HAART) Introduction
11.2.4 Roche Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
11.2.5 Roche Recent Development
11.3 ViiV Healthcare
11.3.1 ViiV Healthcare Company Details
11.3.2 ViiV Healthcare Business Overview
11.3.3 ViiV Healthcare Highly Active Antiretroviral Therapy (HAART) Introduction
11.3.4 ViiV Healthcare Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
11.3.5 ViiV Healthcare Recent Development
11.4 Boehringer Ingelheim
11.4.1 Boehringer Ingelheim Company Details
11.4.2 Boehringer Ingelheim Business Overview
11.4.3 Boehringer Ingelheim Highly Active Antiretroviral Therapy (HAART) Introduction
11.4.4 Boehringer Ingelheim Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
11.4.5 Boehringer Ingelheim Recent Development
11.5 Johnson and Johnson
11.5.1 Johnson and Johnson Company Details
11.5.2 Johnson and Johnson Business Overview
11.5.3 Johnson and Johnson Highly Active Antiretroviral Therapy (HAART) Introduction
11.5.4 Johnson and Johnson Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
11.5.5 Johnson and Johnson Recent Development
11.6 Mylan
11.6.1 Mylan Company Details
11.6.2 Mylan Business Overview
11.6.3 Mylan Highly Active Antiretroviral Therapy (HAART) Introduction
11.6.4 Mylan Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
11.6.5 Mylan Recent Development
11.7 Bionor Pharma
11.7.1 Bionor Pharma Company Details
11.7.2 Bionor Pharma Business Overview
11.7.3 Bionor Pharma Highly Active Antiretroviral Therapy (HAART) Introduction
11.7.4 Bionor Pharma Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
11.7.5 Bionor Pharma Recent Development
11.8 Vertex Pharmaceuticals
11.8.1 Vertex Pharmaceuticals Company Details
11.8.2 Vertex Pharmaceuticals Business Overview
11.8.3 Vertex Pharmaceuticals Highly Active Antiretroviral Therapy (HAART) Introduction
11.8.4 Vertex Pharmaceuticals Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
11.8.5 Vertex Pharmaceuticals Recent Development
11.9 Merck
11.9.1 Merck Company Details
11.9.2 Merck Business Overview
11.9.3 Merck Highly Active Antiretroviral Therapy (HAART) Introduction
11.9.4 Merck Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
11.9.5 Merck Recent Development
11.10 CIPLA
11.10.1 CIPLA Company Details
11.10.2 CIPLA Business Overview
11.10.3 CIPLA Highly Active Antiretroviral Therapy (HAART) Introduction
11.10.4 CIPLA Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
11.10.5 CIPLA Recent Development
11.11 AbbVie
11.11.1 AbbVie Company Details
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Highly Active Antiretroviral Therapy (HAART) Introduction
11.11.4 AbbVie Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
11.11.5 AbbVie Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of Tables
Table 1. Global Highly Active Antiretroviral Therapy (HAART) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Table 3. Key Players of Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Table 4. Key Players of Protease Inhibitor (PI)
Table 5. Global Highly Active Antiretroviral Therapy (HAART) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Highly Active Antiretroviral Therapy (HAART) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Highly Active Antiretroviral Therapy (HAART) Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Highly Active Antiretroviral Therapy (HAART) Market Share by Region (2020-2025)
Table 9. Global Highly Active Antiretroviral Therapy (HAART) Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Highly Active Antiretroviral Therapy (HAART) Market Share by Region (2026-2031)
Table 11. Highly Active Antiretroviral Therapy (HAART) Market Trends
Table 12. Highly Active Antiretroviral Therapy (HAART) Market Drivers
Table 13. Highly Active Antiretroviral Therapy (HAART) Market Challenges
Table 14. Highly Active Antiretroviral Therapy (HAART) Market Restraints
Table 15. Global Highly Active Antiretroviral Therapy (HAART) Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Highly Active Antiretroviral Therapy (HAART) Market Share by Players (2020-2025)
Table 17. Global Top Highly Active Antiretroviral Therapy (HAART) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Highly Active Antiretroviral Therapy (HAART) as of 2024)
Table 18. Ranking of Global Top Highly Active Antiretroviral Therapy (HAART) Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Highly Active Antiretroviral Therapy (HAART) Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Highly Active Antiretroviral Therapy (HAART), Headquarters and Area Served
Table 21. Global Key Players of Highly Active Antiretroviral Therapy (HAART), Product and Application
Table 22. Global Key Players of Highly Active Antiretroviral Therapy (HAART), Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Highly Active Antiretroviral Therapy (HAART) Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Highly Active Antiretroviral Therapy (HAART) Revenue Market Share by Type (2020-2025)
Table 26. Global Highly Active Antiretroviral Therapy (HAART) Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Highly Active Antiretroviral Therapy (HAART) Revenue Market Share by Type (2026-2031)
Table 28. Global Highly Active Antiretroviral Therapy (HAART) Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Highly Active Antiretroviral Therapy (HAART) Revenue Market Share by Application (2020-2025)
Table 30. Global Highly Active Antiretroviral Therapy (HAART) Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Highly Active Antiretroviral Therapy (HAART) Revenue Market Share by Application (2026-2031)
Table 32. North America Highly Active Antiretroviral Therapy (HAART) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Highly Active Antiretroviral Therapy (HAART) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Highly Active Antiretroviral Therapy (HAART) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Highly Active Antiretroviral Therapy (HAART) Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Highly Active Antiretroviral Therapy (HAART) Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Highly Active Antiretroviral Therapy (HAART) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Highly Active Antiretroviral Therapy (HAART) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2026-2031) & (US$ Million)
Table 47. Gilead Company Details
Table 48. Gilead Business Overview
Table 49. Gilead Highly Active Antiretroviral Therapy (HAART) Product
Table 50. Gilead Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025) & (US$ Million)
Table 51. Gilead Recent Development
Table 52. Roche Company Details
Table 53. Roche Business Overview
Table 54. Roche Highly Active Antiretroviral Therapy (HAART) Product
Table 55. Roche Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025) & (US$ Million)
Table 56. Roche Recent Development
Table 57. ViiV Healthcare Company Details
Table 58. ViiV Healthcare Business Overview
Table 59. ViiV Healthcare Highly Active Antiretroviral Therapy (HAART) Product
Table 60. ViiV Healthcare Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025) & (US$ Million)
Table 61. ViiV Healthcare Recent Development
Table 62. Boehringer Ingelheim Company Details
Table 63. Boehringer Ingelheim Business Overview
Table 64. Boehringer Ingelheim Highly Active Antiretroviral Therapy (HAART) Product
Table 65. Boehringer Ingelheim Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025) & (US$ Million)
Table 66. Boehringer Ingelheim Recent Development
Table 67. Johnson and Johnson Company Details
Table 68. Johnson and Johnson Business Overview
Table 69. Johnson and Johnson Highly Active Antiretroviral Therapy (HAART) Product
Table 70. Johnson and Johnson Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025) & (US$ Million)
Table 71. Johnson and Johnson Recent Development
Table 72. Mylan Company Details
Table 73. Mylan Business Overview
Table 74. Mylan Highly Active Antiretroviral Therapy (HAART) Product
Table 75. Mylan Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025) & (US$ Million)
Table 76. Mylan Recent Development
Table 77. Bionor Pharma Company Details
Table 78. Bionor Pharma Business Overview
Table 79. Bionor Pharma Highly Active Antiretroviral Therapy (HAART) Product
Table 80. Bionor Pharma Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025) & (US$ Million)
Table 81. Bionor Pharma Recent Development
Table 82. Vertex Pharmaceuticals Company Details
Table 83. Vertex Pharmaceuticals Business Overview
Table 84. Vertex Pharmaceuticals Highly Active Antiretroviral Therapy (HAART) Product
Table 85. Vertex Pharmaceuticals Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025) & (US$ Million)
Table 86. Vertex Pharmaceuticals Recent Development
Table 87. Merck Company Details
Table 88. Merck Business Overview
Table 89. Merck Highly Active Antiretroviral Therapy (HAART) Product
Table 90. Merck Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025) & (US$ Million)
Table 91. Merck Recent Development
Table 92. CIPLA Company Details
Table 93. CIPLA Business Overview
Table 94. CIPLA Highly Active Antiretroviral Therapy (HAART) Product
Table 95. CIPLA Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025) & (US$ Million)
Table 96. CIPLA Recent Development
Table 97. AbbVie Company Details
Table 98. AbbVie Business Overview
Table 99. AbbVie Highly Active Antiretroviral Therapy (HAART) Product
Table 100. AbbVie Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025) & (US$ Million)
Table 101. AbbVie Recent Development
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
Table 105. Authors List of This Report
List of Figures
Figure 1. Highly Active Antiretroviral Therapy (HAART) Picture
Figure 2. Global Highly Active Antiretroviral Therapy (HAART) Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Highly Active Antiretroviral Therapy (HAART) Market Share by Type: 2024 VS 2031
Figure 4. Nucleoside Reverse Transcriptase Inhibitors (NRTI) Features
Figure 5. Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Features
Figure 6. Protease Inhibitor (PI) Features
Figure 7. Global Highly Active Antiretroviral Therapy (HAART) Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Highly Active Antiretroviral Therapy (HAART) Market Share by Application: 2024 VS 2031
Figure 9. Hospital Case Studies
Figure 10. Clinic Case Studies
Figure 11. Other Case Studies
Figure 12. Highly Active Antiretroviral Therapy (HAART) Report Years Considered
Figure 13. Global Highly Active Antiretroviral Therapy (HAART) Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Highly Active Antiretroviral Therapy (HAART) Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Highly Active Antiretroviral Therapy (HAART) Market Share by Region: 2024 VS 2031
Figure 16. Global Highly Active Antiretroviral Therapy (HAART) Market Share by Players in 2024
Figure 17. Global Top Highly Active Antiretroviral Therapy (HAART) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Highly Active Antiretroviral Therapy (HAART) as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Highly Active Antiretroviral Therapy (HAART) Revenue in 2024
Figure 19. North America Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Highly Active Antiretroviral Therapy (HAART) Market Share by Country (2020-2031)
Figure 21. United States Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Highly Active Antiretroviral Therapy (HAART) Market Share by Country (2020-2031)
Figure 25. Germany Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Highly Active Antiretroviral Therapy (HAART) Market Share by Region (2020-2031)
Figure 33. China Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Highly Active Antiretroviral Therapy (HAART) Market Share by Country (2020-2031)
Figure 41. Mexico Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Highly Active Antiretroviral Therapy (HAART) Market Share by Country (2020-2031)
Figure 45. Turkey Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Gilead Revenue Growth Rate in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
Figure 49. Roche Revenue Growth Rate in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
Figure 50. ViiV Healthcare Revenue Growth Rate in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
Figure 51. Boehringer Ingelheim Revenue Growth Rate in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
Figure 52. Johnson and Johnson Revenue Growth Rate in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
Figure 53. Mylan Revenue Growth Rate in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
Figure 54. Bionor Pharma Revenue Growth Rate in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
Figure 55. Vertex Pharmaceuticals Revenue Growth Rate in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
Figure 56. Merck Revenue Growth Rate in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
Figure 57. CIPLA Revenue Growth Rate in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
Figure 58. AbbVie Revenue Growth Rate in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Table 1. Global Highly Active Antiretroviral Therapy (HAART) Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Key Players of Nucleoside Reverse Transcriptase Inhibitors (NRTI)
Table 3. Key Players of Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
Table 4. Key Players of Protease Inhibitor (PI)
Table 5. Global Highly Active Antiretroviral Therapy (HAART) Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 6. Global Highly Active Antiretroviral Therapy (HAART) Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
Table 7. Global Highly Active Antiretroviral Therapy (HAART) Market Size by Region (2020-2025) & (US$ Million)
Table 8. Global Highly Active Antiretroviral Therapy (HAART) Market Share by Region (2020-2025)
Table 9. Global Highly Active Antiretroviral Therapy (HAART) Forecasted Market Size by Region (2026-2031) & (US$ Million)
Table 10. Global Highly Active Antiretroviral Therapy (HAART) Market Share by Region (2026-2031)
Table 11. Highly Active Antiretroviral Therapy (HAART) Market Trends
Table 12. Highly Active Antiretroviral Therapy (HAART) Market Drivers
Table 13. Highly Active Antiretroviral Therapy (HAART) Market Challenges
Table 14. Highly Active Antiretroviral Therapy (HAART) Market Restraints
Table 15. Global Highly Active Antiretroviral Therapy (HAART) Revenue by Players (2020-2025) & (US$ Million)
Table 16. Global Highly Active Antiretroviral Therapy (HAART) Market Share by Players (2020-2025)
Table 17. Global Top Highly Active Antiretroviral Therapy (HAART) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Highly Active Antiretroviral Therapy (HAART) as of 2024)
Table 18. Ranking of Global Top Highly Active Antiretroviral Therapy (HAART) Companies by Revenue (US$ Million) in 2024
Table 19. Global 5 Largest Players Market Share by Highly Active Antiretroviral Therapy (HAART) Revenue (CR5 and HHI) & (2020-2025)
Table 20. Global Key Players of Highly Active Antiretroviral Therapy (HAART), Headquarters and Area Served
Table 21. Global Key Players of Highly Active Antiretroviral Therapy (HAART), Product and Application
Table 22. Global Key Players of Highly Active Antiretroviral Therapy (HAART), Date of Enter into This Industry
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Highly Active Antiretroviral Therapy (HAART) Market Size by Type (2020-2025) & (US$ Million)
Table 25. Global Highly Active Antiretroviral Therapy (HAART) Revenue Market Share by Type (2020-2025)
Table 26. Global Highly Active Antiretroviral Therapy (HAART) Forecasted Market Size by Type (2026-2031) & (US$ Million)
Table 27. Global Highly Active Antiretroviral Therapy (HAART) Revenue Market Share by Type (2026-2031)
Table 28. Global Highly Active Antiretroviral Therapy (HAART) Market Size by Application (2020-2025) & (US$ Million)
Table 29. Global Highly Active Antiretroviral Therapy (HAART) Revenue Market Share by Application (2020-2025)
Table 30. Global Highly Active Antiretroviral Therapy (HAART) Forecasted Market Size by Application (2026-2031) & (US$ Million)
Table 31. Global Highly Active Antiretroviral Therapy (HAART) Revenue Market Share by Application (2026-2031)
Table 32. North America Highly Active Antiretroviral Therapy (HAART) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 33. North America Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2020-2025) & (US$ Million)
Table 34. North America Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2026-2031) & (US$ Million)
Table 35. Europe Highly Active Antiretroviral Therapy (HAART) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 36. Europe Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2020-2025) & (US$ Million)
Table 37. Europe Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2026-2031) & (US$ Million)
Table 38. Asia-Pacific Highly Active Antiretroviral Therapy (HAART) Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
Table 39. Asia-Pacific Highly Active Antiretroviral Therapy (HAART) Market Size by Region (2020-2025) & (US$ Million)
Table 40. Asia-Pacific Highly Active Antiretroviral Therapy (HAART) Market Size by Region (2026-2031) & (US$ Million)
Table 41. Latin America Highly Active Antiretroviral Therapy (HAART) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 42. Latin America Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2020-2025) & (US$ Million)
Table 43. Latin America Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2026-2031) & (US$ Million)
Table 44. Middle East & Africa Highly Active Antiretroviral Therapy (HAART) Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
Table 45. Middle East & Africa Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2020-2025) & (US$ Million)
Table 46. Middle East & Africa Highly Active Antiretroviral Therapy (HAART) Market Size by Country (2026-2031) & (US$ Million)
Table 47. Gilead Company Details
Table 48. Gilead Business Overview
Table 49. Gilead Highly Active Antiretroviral Therapy (HAART) Product
Table 50. Gilead Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025) & (US$ Million)
Table 51. Gilead Recent Development
Table 52. Roche Company Details
Table 53. Roche Business Overview
Table 54. Roche Highly Active Antiretroviral Therapy (HAART) Product
Table 55. Roche Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025) & (US$ Million)
Table 56. Roche Recent Development
Table 57. ViiV Healthcare Company Details
Table 58. ViiV Healthcare Business Overview
Table 59. ViiV Healthcare Highly Active Antiretroviral Therapy (HAART) Product
Table 60. ViiV Healthcare Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025) & (US$ Million)
Table 61. ViiV Healthcare Recent Development
Table 62. Boehringer Ingelheim Company Details
Table 63. Boehringer Ingelheim Business Overview
Table 64. Boehringer Ingelheim Highly Active Antiretroviral Therapy (HAART) Product
Table 65. Boehringer Ingelheim Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025) & (US$ Million)
Table 66. Boehringer Ingelheim Recent Development
Table 67. Johnson and Johnson Company Details
Table 68. Johnson and Johnson Business Overview
Table 69. Johnson and Johnson Highly Active Antiretroviral Therapy (HAART) Product
Table 70. Johnson and Johnson Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025) & (US$ Million)
Table 71. Johnson and Johnson Recent Development
Table 72. Mylan Company Details
Table 73. Mylan Business Overview
Table 74. Mylan Highly Active Antiretroviral Therapy (HAART) Product
Table 75. Mylan Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025) & (US$ Million)
Table 76. Mylan Recent Development
Table 77. Bionor Pharma Company Details
Table 78. Bionor Pharma Business Overview
Table 79. Bionor Pharma Highly Active Antiretroviral Therapy (HAART) Product
Table 80. Bionor Pharma Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025) & (US$ Million)
Table 81. Bionor Pharma Recent Development
Table 82. Vertex Pharmaceuticals Company Details
Table 83. Vertex Pharmaceuticals Business Overview
Table 84. Vertex Pharmaceuticals Highly Active Antiretroviral Therapy (HAART) Product
Table 85. Vertex Pharmaceuticals Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025) & (US$ Million)
Table 86. Vertex Pharmaceuticals Recent Development
Table 87. Merck Company Details
Table 88. Merck Business Overview
Table 89. Merck Highly Active Antiretroviral Therapy (HAART) Product
Table 90. Merck Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025) & (US$ Million)
Table 91. Merck Recent Development
Table 92. CIPLA Company Details
Table 93. CIPLA Business Overview
Table 94. CIPLA Highly Active Antiretroviral Therapy (HAART) Product
Table 95. CIPLA Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025) & (US$ Million)
Table 96. CIPLA Recent Development
Table 97. AbbVie Company Details
Table 98. AbbVie Business Overview
Table 99. AbbVie Highly Active Antiretroviral Therapy (HAART) Product
Table 100. AbbVie Revenue in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025) & (US$ Million)
Table 101. AbbVie Recent Development
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
Table 105. Authors List of This Report
List of Figures
Figure 1. Highly Active Antiretroviral Therapy (HAART) Picture
Figure 2. Global Highly Active Antiretroviral Therapy (HAART) Market Size Comparison by Type (2020-2031) & (US$ Million)
Figure 3. Global Highly Active Antiretroviral Therapy (HAART) Market Share by Type: 2024 VS 2031
Figure 4. Nucleoside Reverse Transcriptase Inhibitors (NRTI) Features
Figure 5. Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Features
Figure 6. Protease Inhibitor (PI) Features
Figure 7. Global Highly Active Antiretroviral Therapy (HAART) Market Size by Application (2020-2031) & (US$ Million)
Figure 8. Global Highly Active Antiretroviral Therapy (HAART) Market Share by Application: 2024 VS 2031
Figure 9. Hospital Case Studies
Figure 10. Clinic Case Studies
Figure 11. Other Case Studies
Figure 12. Highly Active Antiretroviral Therapy (HAART) Report Years Considered
Figure 13. Global Highly Active Antiretroviral Therapy (HAART) Market Size (US$ Million), Year-over-Year: 2020-2031
Figure 14. Global Highly Active Antiretroviral Therapy (HAART) Market Size, (US$ Million), 2020 VS 2024 VS 2031
Figure 15. Global Highly Active Antiretroviral Therapy (HAART) Market Share by Region: 2024 VS 2031
Figure 16. Global Highly Active Antiretroviral Therapy (HAART) Market Share by Players in 2024
Figure 17. Global Top Highly Active Antiretroviral Therapy (HAART) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Highly Active Antiretroviral Therapy (HAART) as of 2024)
Figure 18. The Top 10 and 5 Players Market Share by Highly Active Antiretroviral Therapy (HAART) Revenue in 2024
Figure 19. North America Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 20. North America Highly Active Antiretroviral Therapy (HAART) Market Share by Country (2020-2031)
Figure 21. United States Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 22. Canada Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 23. Europe Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 24. Europe Highly Active Antiretroviral Therapy (HAART) Market Share by Country (2020-2031)
Figure 25. Germany Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 26. France Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 27. U.K. Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 28. Italy Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 29. Russia Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 30. Nordic Countries Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 31. Asia-Pacific Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 32. Asia-Pacific Highly Active Antiretroviral Therapy (HAART) Market Share by Region (2020-2031)
Figure 33. China Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 34. Japan Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 35. South Korea Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 36. Southeast Asia Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 37. India Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 38. Australia Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 39. Latin America Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 40. Latin America Highly Active Antiretroviral Therapy (HAART) Market Share by Country (2020-2031)
Figure 41. Mexico Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 42. Brazil Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 43. Middle East & Africa Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 44. Middle East & Africa Highly Active Antiretroviral Therapy (HAART) Market Share by Country (2020-2031)
Figure 45. Turkey Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 46. Saudi Arabia Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 47. UAE Highly Active Antiretroviral Therapy (HAART) Market Size YoY Growth (2020-2031) & (US$ Million)
Figure 48. Gilead Revenue Growth Rate in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
Figure 49. Roche Revenue Growth Rate in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
Figure 50. ViiV Healthcare Revenue Growth Rate in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
Figure 51. Boehringer Ingelheim Revenue Growth Rate in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
Figure 52. Johnson and Johnson Revenue Growth Rate in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
Figure 53. Mylan Revenue Growth Rate in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
Figure 54. Bionor Pharma Revenue Growth Rate in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
Figure 55. Vertex Pharmaceuticals Revenue Growth Rate in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
Figure 56. Merck Revenue Growth Rate in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
Figure 57. CIPLA Revenue Growth Rate in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
Figure 58. AbbVie Revenue Growth Rate in Highly Active Antiretroviral Therapy (HAART) Business (2020-2025)
Figure 59. Bottom-up and Top-down Approaches for This Report
Figure 60. Data Triangulation
Figure 61. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Krypton Flash Lamp Market Research Report 2025
May 12, 25
Global IR Halogen Lamp Market Research Report 2025
May 12, 25
Global Halogen IR Lamp Market Research Report 2025
May 12, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232